About: COVID-19 Associated Pulmonary Aspergillosis (CAPA)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID-19 Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment
Creator	Cornely, Oliver Carvalho, Agostinho Lass-Flörl, Cornelia Krause, Robert Perlin, David Van De Veerdonk, Frank Hoenigl, Martin Koehler, Philipp Arastehfar, Amir Jenks, Jeffrey
Source	Medline; PMC
abstract	Like severe influenza, coronavirus disease-19 (COVID-19) resulting in acute respiratory distress syndrome (ARDS) has emerged as an important disease that predisposes patients to secondary pulmonary aspergillosis, with 35 cases of COVID-19 associated pulmonary aspergillosis (CAPA) published until June 2020. The release of danger-associated molecular patterns during severe COVID-19 results in both pulmonary epithelial damage and inflammatory disease, which are predisposing risk factors for pulmonary aspergillosis. Moreover, collateral effects of host recognition pathways required for the activation of antiviral immunity may, paradoxically, contribute to a highly permissive inflammatory environment that favors fungal pathogenesis. Diagnosis of CAPA remains challenging, mainly because bronchoalveolar lavage fluid galactomannan testing and culture, which represent the most sensitive diagnostic tests for aspergillosis in the ICU, are hindered by the fact that bronchoscopies are rarely performed in COVID-19 patients due to the risk of disease transmission. Similarly, autopsies are rarely performed, which may result in an underestimation of the prevalence of CAPA. Finally, the treatment of CAPA is complicated by drug–drug interactions associated with broad spectrum azoles, renal tropism and damage caused by SARS-CoV-2, which may challenge the use of liposomal amphotericin B, as well as the emergence of azole-resistance. This clinical reality creates an urgency for new antifungal drugs currently in advanced clinical development with more promising pharmacokinetic and pharmacodynamic profiles.
has issue date	2020-06-24(xsd:dateTime)
bibo:doi	10.3390/jof6020091
bibo:pmid	32599813
has license	cc-by
sha1sum (hex)	4805c92e430cf24091cfd2076d538b9ef2d351ba
schema:url	https://doi.org/10.3390/jof6020091
resource representing a document's title	COVID-19 Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment
has PubMed Central identifier	PMC7346000
has PubMed identifier	32599813
schema:publication	J Fungi (Basel)
resource representing a document's body	covid:4805c92e430cf24091cfd2076d538b9ef2d351ba#body_text
is schema:about of	named entity 'COVID-19' named entity 'COVID-19' named entity 'Excellence' named entity 'Diagnosis' named entity 'Infection' named entity 'ASSOCIATED' named entity 'ANTIVIRAL' named entity 'CASES' named entity 'EPITHELIAL DAMAGE' named entity 'highly' named entity 'danger-associated molecular patterns' named entity 'Diagnosis' named entity 'aspergillosis' named entity 'trachea' named entity 'COVID-19' named entity 'blood samples' named entity 'MedPace' named entity 'medical conditions' named entity 'Aspergillus' named entity 'biomarker' named entity 'antifungals' named entity 'Treatment of Cancer' named entity 'COVID-19' named entity 'PCR' named entity 'Viral entry' named entity 'type II pneumocytes' named entity 'virus' named entity 'IL-1β' named entity 'kinin' named entity 'systemic corticosteroids' named entity 'drug-drug interactions' named entity 'immune cells' named entity 'COVID-19' named entity 'Pfizer' named entity 'chronic rhinosinusitis' named entity 'bioavailability' named entity 'serum' named entity 'hyperinflammation' named entity 'serum' named entity 'aspirate' named entity 'COVID-19' named entity '4/9' named entity 'therapeutic drug monitoring' named entity 'receptor' named entity 'amphotericin' named entity 'spike protein' named entity 'IL-1' named entity 'Toll-like receptors' named entity 'France' named entity 'bacteria' named entity 'infection' named entity '4/35' named entity 'kidney injury' named entity 'voriconazole' named entity 'antifungal treatment' named entity 'influenza' named entity 'COVID-19' named entity 'acute lung injury' named entity 'upregulation' named entity 'Aspergillus' named entity 'Astellas' named entity 'IPA' named entity 'COVID-19' named entity 'Aspergillus' named entity 'antifungal drugs' named entity 'TMPRSS2' named entity 'antifungal prophylaxis' named entity 'Aspergillus' named entity 'SARS-CoV-2 virus' named entity 'IL-6' named entity 'A. fumigatus' named entity 'kallikrein'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software